Filing exhibits
- 8-K Current report
- 4.1 Convertible Promissory Note In the Principal Amount of $100,000, Dated July 19, 2022, Between Immune Therapeutics, Inc. and Kevin Phelps
- 4.2 Convertible Promissory Note In the Principal Amount of $100,000, Dated July 19, 2022, Between Immune Therapeutics, Inc. and Kevin Phelps
- 4.3 Convertible Promissory Note In the Principal Amount of $200,000, Dated July 19, 2022, Between Immune Therapeutics, Inc. and Kevin Phelps
- 10.1 Separation and Release Agreement, Dated July 19, 2022, Between Kevin Phelps and Immune Therapeutics, Inc.
- 99.1 Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
- Download Excel data file
- View Excel data file
Table of Contents